**RESEARCH**

**Significant increase in azithromycin “resistance” and susceptibility to ceftriaxone and cefixime in *Neisseria gonorrhoeae* isolates in 26 European countries, 2019**

Michaela J. Day1*, Susanne Jacobsson2, Gianfranco Spiteri3, Carina Kulisev1, Noshin Sajedi1, Neil Woodford1, Benjamin Blumel3, Marieke J. van der Werf3, Andrew J. Amato‑Gauci3, Magnus Unemo2,4† and Michelle J. Cole1† on behalf of The Euro‑GASP network3

**Abstract**

**Background:** The European Gonococcal Antimicrobial Surveillance Programme (Euro‑GASP) performs annual sentinel surveillance of *Neisseria gonorrhoeae* susceptibility to therapeutically relevant antimicrobials across the European Union/European Economic Area (EU/EEA). We present the Euro‑GASP results from 2019 (26 countries), linked to patient epidemiological data, and compared with data from previous years.

**Methods:** Agar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to determine the antimicrobial susceptibility (using EUCAST clinical breakpoints, where available) of 3239 *N. gonorrhoeae* isolates from 26 countries across the EU/EEA. Significance of differences compared with Euro‑GASP results in previous years was analysed using Z‑test and the Pearson’s χ2 test was used to assess significance of odds ratios for associations between patient epidemiological data and antimicrobial resistance.

**Results:** European *N. gonorrhoeae* isolates collected between 2016 and 2019 displayed shifting MIC distributions for; ceftriaxone, with highly susceptible isolates increasing over time and occasional resistant isolates each year; cefixime, with highly‑susceptible isolates becoming increasingly common; azithromycin, with a shift away from lower MICs towards higher MICs above the EUCAST epidemiological cut‑off (ECOFF); and ciprofloxacin which is displaying a similar shift in MICs as observed for azithromycin. In 2019, two isolates displayed ceftriaxone resistance, but both isolates had MICs below the azithromycin ECOFF. Cefixime resistance (0.8%) was associated with patient sex, with resistance higher in females compared with male heterosexuals and men‑who‑have‑sex‑with‑men (MSM). The number of countries reporting isolates with azithromycin MICs above the ECOFF increased from 76.9% (20/26) in 2016 to 92.3% (24/26) in 2019. Isolates with azithromycin MICs above the ECOFF (9.0%) were associated with pharyngeal infection sites. Following multivariable analysis, ciprofloxacin resistance remained associated with isolates from MSM and heterosexual males compared with females, the absence of a concurrent chlamydial infection, pharyngeal infection sites and patients ≥ 25 years of age.

---

1†Magnus Unemo and Michelle J. Cole joint senior authors

*Correspondence: Michaela.Day@phe.gov.uk

1 UK Health Security Agency, London, UK

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: Resistance to ceftriaxone and cefixime remained uncommon in EU/EEA countries in 2019 with a significant decrease in cefixime resistance observed between 2016 and 2019. The significant increase in azithromycin “resistance” (azithromycin MICs above the ECOFF) threatens the effectiveness of the dual therapy (ceftriaxone + azithromycin), i.e., for ceftriaxone-resistant cases, currently recommended in many countries internationally and requires close monitoring.

Keywords: Gonorrhoea, Treatment, Antimicrobial resistance, Ceftriaxone, Azithromycin, Surveillance, European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), Europe, European Union (EU), European Economic Area (EEA)

Background

The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) is a sentinel surveillance system that since 2009 has been coordinated by the European Centre for Disease Prevention and Control (ECDC) and supported by a European network of microbiologists and epidemiologists. The programme aims to provide quality-assured antimicrobial susceptibility data to inform European and other regional and national gonorrhoea treatment guidelines as well as to detect emerging antimicrobial resistance and monitor trends in antimicrobial resistance.

Decreasing levels of susceptibility to clinically relevant antimicrobials along with verified treatment failures are threatening the treatment and control of gonorrhoea internationally [1–9]. The European guideline for the diagnosis and treatment of gonorrhoea in adults was updated in 2020 [10, 11]. The guideline now recommends for uncomplicated *N. gonorrhoeae* infections, 1 g ceftriaxone (an increase from the 500 mg recommended in the 2012 guidelines [12]) with 2 g azithromycin, or 1 g ceftriaxone alone in settings where in vitro antimicrobial susceptibility surveillance has shown lack of ceftriaxone resistance, test of cure (TOC) is mandatory, and doxycycline regimen is administered if *Chlamydia trachomatis* infection has not been excluded [10]. Notably, in a most recent Euro-GASP survey of 26 EU/EEA countries only 19 (73.1%) countries used ceftriaxone plus azithromycin dual therapy with Ireland, Sweden, the Netherlands and the United Kingdom (UK) having national guidelines that recommended use of ceftriaxone 1 g monotherapy [13].

In addition, cefixime (400 mg single dose) is recommended in the European guideline only as a substitute for ceftriaxone in dual therapy in cases where injections are refused or contraindicated. Cefixime is not recommended for use in monotherapy. Ciprofloxacin (500 mg single dose) is suggested as an alternative treatment regime for those with history of severe hypersensitivity to any β-lactam antimicrobial or when injections are contraindicated or refused, however, only where susceptibility has been confirmed phenotypically or molecularly (gyrA-based resistance testing) [10].

As azithromycin is only recommended for use in dual therapy with another effective agent, the correlates between azithromycin in vitro susceptibility and treatment outcome are limited, and appropriate clinical treatment data to inform clinical breakpoints are lacking, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) replaced their clinical resistance breakpoint with an epidemiological cut-off (ECOFF) value of 1 mg/L in January 2019 [14]. This ECOFF value aims to detect strains with acquired macrolide resistance. Those with azithromycin MICs of ≤ 1 mg/L are considered “wild-type” [14]. Euro-GASP previously reported stable levels of azithromycin resistance (approx. 7%, using previous > 0.5 mg/L breakpoint) across the EU/EEA in 2014–2016 [7].

In the present study, we describe the results from the 2019 Euro-GASP sentinel surveillance, in conjunction with patients’ epidemiological data, and compare them to the Euro-GASP results obtained from previous years (main focus on the published 2016 Euro-GASP data [7]).

Methods

European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)

Annually, laboratories participating in Euro-GASP report antimicrobial susceptibility profiles (using EUCAST clinical breakpoints, where available [14]) and patient epidemiological data for *N. gonorrhoeae* isolates collected in their country as described previously [7, 15]. All gonococcal isolates were cultured and preserved as part of the routine diagnostics (standard care), and isolates or data were submitted to the Euro-GASP surveillance study with no patient identification information, separate ethical approval was therefore not required.

In 2019, 26 countries participated in Euro-GASP, submitting total data for 4166 *N. gonorrhoeae* isolates (one isolate per patient per gonorrhoea episode) to The European Surveillance System (TESSy) at ECDC. Some countries were over-represented in the complete 2019 TESSy data set with Austria submitting data for 434 isolates, France 243 isolates, the Netherlands 364 isolates and Norway 641 isolates whereas other countries with lower
gonorrhoea incidence were under-represented with Cyprus submitting data for two isolates, Latvia seven isolates, Estonia eight isolates and Croatia nine isolates. The same imbalance was also present in previous years’ TESSy datasets. In order to reduce biases caused by high isolate numbers from some countries, only data for the first 200 isolates with complete antimicrobial susceptibility testing results submitted to TESSy in each year were included in the analysis of the present paper including data from 2016 which was used as the main comparator for this publication unless otherwise stated. For comparison of azithromycin MIC data, data collected prior to the introduction of the ECOFF was converted to equal to or below the ECOFF (referred to as susceptible hereafter) or above the ECOFF (referred to as resistant hereafter). Azithromycin MICs ≥256 mg/L will be discussed as “high-level azithromycin resistant”.

### Statistical analysis
The Mann–Whitney test was used to analyse differences in age distribution and the Z-test was applied to compare proportions when analysing antimicrobial susceptibility and epidemiological data. Associations between epidemiological characteristics and antimicrobial susceptibility were assessed using odds ratios (OR) and 95% confidence intervals (CI); the Pearson’s χ² test was used to measure if these odds ratios differed significantly from 1. For small cell numbers (n < 5), Fisher’s exact test was performed. Statistical significance for all tests was assumed when p < 0.05. Statistical analysis was performed using Stata v15 (StataCorp LP, Texas, USA).

### Results
Using a maximum of 200 isolates per country, 3239 N. gonorrhoeae isolates collected in 2019 from 3239 episodes of gonorrhoea were compared to the Euro-GASP data from 2016 (n = 2556) (Table 1). As in all previous years of Euro-GASP surveillance (starting in 2009), most isolates in 2019 were from male patients (84.2%, 2676/3178), and male patients (median age 30 years) were older than female patients (median age 26 years) (p < 0.0001). Overall, patient ages ranged from 0 to 84 years with a median age of 29 years old. The anatomical site of collection was mainly urogenital (71.5%), however, there was a decrease in samples from this site compared to 2016 (75.1%; p = 0.004, Table 1).

In contrast, there was an increase in both rectal (14.2% vs. 16.4%, p = 0.02) and pharyngeal (6.6% vs. 9.0%, p = 0.001) sites which is likely a consequence of the significant increase in specimens from men-who-have-sex-with-men (MSM) in 2019 (41.9% vs. 46.5%, p = 0.0002, Table 1). For cases where information was available, 23.2% (228/981) had a previous gonorrhoea infection which was an increase from 16.7% (163/976) in 2016 (p < 0.002) and 21.2% (228/1075) had a concurrent C. trachomatis infection which remained at a level similar to that in 2016 (23.5%, 181/771) (Table 1). Among cases with known sexual orientation and sex (unknown for 31–43% of cases each year), 53.5% (1046/1954) of the N. gonorrhoeae infections were reported as heterosexually acquired (47.9% females and 52.1% males). The proportion of heterosexual

| Table 1 Gonorrhoea patient characteristics in 2016 and 2019 |
|-------------|----------------|----------------|
|             | 2016 N (%)     | 2019 N (%)     |
| Total number of isolates<sup>a</sup> | 2559           | 3239           |
| Sex          |                |                |
| Male         | 2158 (84.7)    | 2676 (84.2)    |
| Female       | 391 (15.3)     | 502 (15.8)     |
| Not reported | 10             | 61             |
| Age (years)  |                |                |
| < 25         | 668 (26.5)     | 883 (28.4)     |
| ≥ 25         | 1854 (73.5)    | 2223 (71.6)    |
| Not reported | 37             | 133            |
| Sexual orientation and sex |                |                |
| Females      | 391 (24.4)     | 501 (25.6)     |
| Heterosexual males | 539 (33.6) | 545 (27.9)<sup>*</sup> |
| Men who have sex with men       | 672 (41.9)     | 908 (46.5)<sup>*</sup> |
| Not reported | 957            | 1285           |
| Site of infection                |                |                |
| Urogenital    | 1745 (71.5)    | 2076 (71.5)<sup>*</sup> |
| Pharyngeal    | 153 (6.6)      | 262 (9.0)<sup>*</sup> |
| Anorectal     | 329 (14.2)     | 475 (16.4)<sup>*</sup> |
| Other         | 97 (4.2)       | 91 (3.1)<sup>*</sup> |
| Not reported  | 235            | 335            |
| Previous gonorrhoea               |                |                |
| Yes           | 163 (16.7)     | 228 (23.2)<sup>*</sup> |
| No            | 814 (83.3)     | 753 (76.8)<sup>*</sup> |
| Not reported  | 1582           | 2258           |
| Concurrent sexually transmitted infection (STI) |                |                |
| Concurrent chlamydia infection     | 181 (23.5)     | 228 (21.2)     |
| Concurrent other STI (not HIV)     | 51 (6.6)       | 83 (7.7)       |
| No concurrent STI                   | 539 (69.9)     | 764 (71.1)     |
| Not reported | 1788           | 2164           |
| HIV status        |                |                |
| Positive        | 143 (15.8)     | 139 (13.1)     |
| Negative       | 760 (84.2)     | 926 (86.9)     |
| Not reported   | 1656           | 2174           |

<sup>a</sup>Total number of isolates includes a maximum of 200 isolates per country. Three countries exceeded the 200 isolate limit in 2016; The Netherlands, Spain and the UK. In 2019 seven countries exceeded 200 isolates; Austria, Finland, France, The Netherlands, Norway, Spain and the UK.

<sup>*</sup>Bold letters indicate significant difference between 2016 and 2019 by Z-test (p < 0.05)
males decreased from 33.6% in 2016 to 27.9% in 2019 (p = 0.0002, Table 1).

In 2019 ceftriaxone resistance was detected in two urogenital isolates, one in Belgium (MIC = 0.5 mg/L) and one in Portugal (MIC = 0.25 mg/L). Both isolates were also resistant to cefixime (MIC = 2 mg/L and ≤ 0.5 mg/L, respectively) and ciprofloxacin (MIC > 32 mg/L and 4 mg/L, respectively) but were susceptible to azithromycin (MIC 0.5 mg/L and 1 mg/L, respectively). For comparison, there were three urogenital isolates with ceftriaxone resistance identified in 2018 (two in Spain, one in Germany), zero in 2017 and 2016. Despite the detection of ceftriaxone-resistant isolates in both 2018 and 2019, the proportion of gonococcal isolates that were most susceptible to ceftriaxone (MIC ≤ 0.016 mg/L) increased from 82.9% (2117/2555) in 2016 to 89.7% (2671/2933) in 2019 (p < 0.0002, Fig. 1a). In addition, the proportion of isolates with decreased susceptibility to ceftriaxone (MICs from 0.032 to 0.125 mg/L) decreased from 17.1% (438/2555) in 2016 to 10.3% (333/3238) in 2019 (p < 0.0002, Fig. 1a).

Similarly to ceftriaxone, the proportion of isolates most susceptible to cefixime (MIC ≤ 0.016 mg/L) increased from 74.9% (1805/2411) in 2016 to 80.9% (2421/3239) in 2019 (p < 0.0002, Fig. 1b). Furthermore, the percentage of isolates with decreased susceptibility to cefixime (MICs from 0.032 to 0.125 mg/L) decreased from 22.9% (553/2411) in 2016 to 18.3% (592/3239) in 2019 (p < 0.0002). The proportion of cefixime-resistant isolates (MIC > 0.125 mg/L) also decreased from 2.2% (53/2411) in 2016 to 0.8% (26/3239) in 2019 (p < 0.0002, Fig. 1b). Of the 26 isolates with cefixime resistance in 2019, only one had additional azithromycin resistance (MIC = 16 mg/L). In 2019, cefixime resistance was associated with patient sex and sexual orientation with 1.6% resistance in females compared with 0.7% in male heterosexuals and 0.3% in MSM (p = 0.045, Fisher’s exact test, Table 2).

The percentage of isolates with azithromycin resistance (MICs above the ECOFF of 1 mg/L) increased from 3.8% (97/2532) in 2016 to 9.0% (284/3159) in 2019 (p < 0.002, Fig. 1c). In contrast to what was observed for ceftriaxone and cefixime (Fig. 1a and b), there was also a decrease in the proportion of gonococcal isolates with the lowest azithromycin MICs (≤ 0.016 mg/L) from 1.1% (27/2532) in 2016 to 0.4% (14/3159) in 2019 (p < 0.002, Fig. 1c). The proportion of isolates with azithromycin MICs ≥ 256 mg/L (“high-level azithromycin resistance”) has not changed with 0.2% (5/2532) in 2016 and 0.3% in 2019 (10/3159, p = 0.381). Only five countries have reported isolates with azithromycin MICs ≥ 256 mg/L in multiple years; Finland (two in 2016, one in 2017), Iceland (one in 2016, one in 2018, three in 2019), Iceland (two in 2016, two in 2019), Italy (two in 2016, one in 2018), and the UK (one in 2017, six in 2019). The proportion of countries reporting isolates with azithromycin resistance increased from 76.9% (20/26) in 2016 to 92.3% (24/26) in 2019 (p = 0.0007). The countries with the highest proportion of azithromycin-resistant isolates in 2019 were Norway (16%; 32/200), Poland (18.9%; 10/53), Iceland (20.4%; 11/54), Estonia (25%; 2/8), and Croatia (55.6%; 5/9).

Three of these countries, Estonia, Croatia and Poland did not report any azithromycin resistance in 2016, however, the number of isolates reported especially in Estonia and Croatia in both 2016 and 2019 were very low. Azithromycin resistance was associated with pharyngeal sites when compared to urogenital ones (Table 2).

There was an increase in resistance to ciprofloxacin from 47.2% (1003/2124) in 2016 to 57.4% (1665/2884) in 2019 (p < 0.0002, Fig. 1d). The MIC distribution changed between 2016 and 2019 with decreases in lower MICs (0.004–0.008 mg/L, p < 0.0002) and increases in lower levels of resistance (0.5–4 mg/L, p < 0.0002, Fig. 1d).

However, there was a decrease in high-level ciprofloxacin resistance (MIC ≥ 32 mg/L) from 12.4% (264/2124) in 2016 to 7.7% in 2019 (223/2884, p < 0.0002). As in 2016, ciprofloxacin resistance in 2019 was associated with male heterosexuals (compared to females) and previous gonorrhoea infection. In 2019 ciprofloxacin resistance was also associated with MSM (compared to females), patient age ≥ 25 years (compared to < 25 years), anorectal and pharyngeal sites (compared to urogenital) and with not having concurrent C. trachomatis infection (Table 2). Following multivariable analysis, ciprofloxacin resistance remained associated with isolates from MSM (OR = 2.7, CI = 1.48–4.95, p < 0.01) and heterosexual males (OR = 2.24, CI = 1.24–4.05, p < 0.01) compared to females, the absence of a concurrent C. trachomatis infection (OR = 1.9, CI = 1.14–3.18, p = 0.02), pharyngeal sites (OR = 2.4, CI = 1.28–4.52, p < 0.01) and patient age ≥ 25 years (OR = 1.62, CI = 1.05–2.50, p = 0.03).

Discussion

Three distinct antimicrobial susceptibility patterns among N. gonorrhoeae isolates in the EU/EEA have emerged for ceftriaxone, cefixime and azithromycin between 2016 and 2019. Ceftriaxone appears to be shifting towards higher susceptibility over time and resistant isolates continue to be rare. However, worryingly the clonally expanding and internationally spreading ceftriaxone-resistant N. gonorrhoeae strain FC428 has been identified in several EU/EEA countries such as Denmark [16], France [5], Ireland [17], and the UK [18], as well as in many additional countries worldwide, e.g., Japan [19], Australia [20], Canada [21], and China [22].

Cefixime MICs are also shifting away from resistance with highly susceptible isolates becoming increasingly
Fig. 1 Minimum inhibitory concentration (MIC; mg/L) distribution in European Neisseria gonorrhoeae isolates (2016–2019) for a ceftriaxone, b cefixime, c azithromycin, and d ciprofloxacin
common between 2016 and 2019. This increase in cefixime susceptibility might be due to the use of recommended ceftriaxone/azithromycin dual therapy since 2012 or ceftriaxone monotherapy (500–1000 mg), which has become increasingly common in the most recent years in the EU/EEA countries. The same shift towards cefixime susceptibility was observed in the United States (US) between 2014 and 2018 with the proportion of isolates with decreased susceptibility to cefixime (MIC 0.032–0.125 mg/L) decreasing from 37.8 to 29.9% and the
Table 2  Univariate association of cefixime, azithromycin and ciprofloxacin resistance/susceptibility and patient characteristics, 2019

|                              | Cefixime resistance | Azithromycin resistance | Ciprofloxacin resistance |
|------------------------------|---------------------|-------------------------|--------------------------|
|                              | N (%, 95% CI)       | Odds ratio              | 95% CI                   | p value       |
|                              |                     | N (%, 95% CI)           | Odds ratio              | 95% CI       | p value |
|                              |                     |                         |                         |              |
| **Site of infection (n = 2904)** |                     |                         |                         |              |
| Urogenital (2076)            | 18 (0.9, 0.5–1.4)   | 0.40*                   | 171 (8.2, 7.1–9.5)       | 1            |
| Anorectal (475)              | 1 (0.2, 0.0–1.2)    |                         | 48 (10.1, 7.7–13.1)      | 1.25         | 0.09–1.75 | 0.19 |
| Pharyngeal (262)             | 2 (0.8, 0.2–2.7)    |                         | 35 (13.4, 9.8–18.0)      | 1.72         | 1.16–2.54 | <0.01 |
| Other (91)                   | 1 (1.1, 0.2–2.7)    |                         | 9 (9.9, 5.3–17.7)        | 1.22         | 0.60–2.48 | 0.58 |
| **Sexual orientation and sex (n = 1955)** |                     |                         |                         |              |
| MSM (908)                    | 3 (0.3, 0.1–1.0)    | **0.045**               | 75 (8.3, 6.6–10.2)       | 1            |
| Male heterosexual (545)      | 4 (0.7, 0.3–1.9)    |                         | 40 (7.3, 5.4–9.8)        | 0.88         | 0.59–1.31 | 0.53 |
| Female (502)                 | 8 (1.6, 0.8–3.1)    |                         | 35 (7.0, 5.0–9.5)        | 0.83         | 0.59–1.26 | 0.39 |
| **Previous gonorrhoea (n = 981)** |                     |                         |                         |              |
| Yes (228)                    | 1 (0.4, 0.0–2.4)    | 0.041*                  | 18 (7.9, 6.0–9.8)        | 1.03         | 0.59–1.78 | 0.92 |
| No (753)                     | 1 (0.1, 0.0–0.8)    |                         | 58 (7.7, 5.1–12.1)       | 1            |
| **Concurrent chlamydia (n = 1075)** |                     |                         |                         |              |
| Yes (228)                    | 2 (0.9, 0.2–3.1)    | 0.020*                  | 20 (8.8, 5.8–13.2)       | 1.02         | 0.61–1.71 | 0.94 |
| No (847)                     | 2 (0.0, 0.0–0.9)    |                         | 73 (8.6, 7.0–10.7)       | 1            |
| **HIV status (n = 1065)**    |                     |                         |                         |              |
| Positive (139)               | 0 (0.0, 0.0–2.7)    | **1.00**                | 15 (10.8, 6.6–17.0)      | 1.25         | 0.70–2.23 | 0.46 |
| Negative (926)               | 3 (0.3, 0.1–0.9)    |                         | 82 (8.9, 7.2–10.9)       | 1            |
| **Age (n = 3106)**           |                     |                         |                         |              |
| <25 years (883)              | 7 (0.8, 0.4–1.6)    | 1.072                   | 75 (8.5, 6.8–10.5)       | 1            |
| ≥25 years (2223)             | 15 (0.7, 0.4–1.1)   | 0.85                    | 193 (8.7, 7.6–9.9)       | 1.02         | 0.77–1.35 | 0.87 |

MSM men who have sex with men. Bold letters indicate significance

*Fishers exact test (n < 5)

a One isolate had no ciprofloxacin result

b Two isolates had no ciprofloxacin results
proportion of cefixime-resistant isolates decreasing from 0.7 to 0.3% (recalculated from data presented in [23]). In the US, new gonorrhoea treatment guidelines were issued in 2015 recommending dual therapy with ceftriaxone 500 mg and azithromycin 1 g for uncomplicated gonorrhoea [24], which may have had a role in the increase in cefixime susceptibility.

Azithromycin MICs are, in contrast to those observed for ceftriaxone and cefixime, shifting towards MICs above the azithromycin ECOFF, and this has been recently reported in many countries internationally [8, 9, 25]. High levels of azithromycin resistance are of concern not just for N. gonorrhoeae but for also for other bacterial STIs. The same increase in higher MICs (>1 mg/L) was observed in the US between 2014 and 2018 although less pronounced than in Europe with an increase from 2.4 to 4.6% (recalculated from data presented in [23]). By contrast, the Australian gonococcal surveillance programme has observed a decrease in the percentage of isolates with azithromycin MICs >1 mg/L after the peak of 9.3% was reached in 2017 to 4.6% in 2019 [26]. In the vast majority of Australian settings, dual therapy with ceftriaxone 500 mg and azithromycin 1 g (2 g for pharyngeal gonorrhoea) is recommended for uncomplicated gonorrhoea [27]. This may indicate a high adherence to recommended treatment, less and more controlled macrolide use for other infections (particularly Chlamydia trachomatis and Mycoplasma genitalium infections), and/or replacement of some major azithromycin-resistant gonococcal clones with more azithromycin-susceptible clones.

In the Euro-GASP 2009–2016 data, ciprofloxacin resistance was significantly associated with urogenital sites [28], in 2019 both ciprofloxacin and azithromycin resistance were significantly associated with pharyngeal infections. Pharyngeal infections are considered to have a major role in the development of resistance to several antimicrobials, such as beta-lactam antimicrobials. The presence of other commensal Neisseria species in the pharynx often with previous exposure to antibiotics allows for horizontal transfer of resistance genes to N. gonorrhoeae [29–33]. Pharyngeal infections are also more difficult to eradicate with most antimicrobials due to sub-optimal antibiotic concentrations at this site which adds to the selective pressure of gonococcal clones with higher MICs [34, 35].

The limitations of Euro-GASP and, accordingly, the present study have been previously described in detail [7, 28, 36, 37]. These limitations include, for example, that a limited number of gonorrhoea patients and N. gonorrhoeae isolates (~3% of all reported gonorrhoea cases in the EU/EEA) from many diverse countries are examined, many gonorrhoea cases in the EU/EEA are diagnosed with molecular diagnostics and no N. gonorrhoeae isolates are available from many of these cases, the majority of examined N. gonorrhoeae isolates are obtained from urogenital sites and the number of isolates from rectal and pharyngeal sites are more limited, and in many countries the completeness of reported epidemiological data (particularly of sexual orientation) is suboptimal. However, despite these limitations a previous representativeness analysis showed that Euro-GASP appropriately reflects the antimicrobial resistance situation for N. gonorrhoeae in the EU/EEA [36].

Conclusions

Resistance in N. gonorrhoeae to the third-generation cephalosporins ceftriaxone and cefixime remained uncommon in 2019 in EU/EEA countries with a significant decrease in cefixime resistance observed between 2016 and 2019. The significant increase in the proportion of isolates with azithromycin resistance is concerning for the future effectiveness of any ceftriaxone plus azithromycin dual therapy, particularly if ceftriaxone resistance starts to spread more widely. It is imperative that the MICs for N. gonorrhoeae isolates continue to be monitored very closely over the next years, particularly of azithromycin and ceftriaxone.

Abbreviations

AD: Agar dilution method; CI: Confidence interval; ECDC: European Centre for Disease Prevention and Control; ECOFF: Epidemiological cut-off; EEA: European Economic Area; EU: European Union; EUCAST: European Committee on Antimicrobial Susceptibility Testing; Euro-GASP: European Gonococcal Antimicrobial Surveillance Programme; MIC: Minimum inhibitory concentration; MSM: Men who have sex with men; No.: Number; OR: Odds ratio; STI: Sexually transmitted infection; TESSy: The European Surveillance System; UK: United Kingdom.

Acknowledgements

We are grateful to the European STI surveillance network for its contribution to developing and implementing Euro-GASP and submitting gonococcal isolates and epidemiological data. The Euro-GASP Network: Austrian Agency for Health and Food Safety, Wien, Austria; Claudia Eder, Sonja Pleininger, Steliana Huhliscu; Institute of Tropical Medicine, Antwerp, Belgium: Irith de Baetser; Croatian National Institute Of Public Health, Zagreb, Croatia; Blaženka Hunjak, Tatjana Nemeth Blažic; Nicosa General Hospital, Nikosia, Cyprus; Panagiota Makats-Charakalmpous, Despo Perisidou; The National Institute of Public Health, Prague, The Czech Republic: Hana Zákovácká, Helena Zemičková; Statens Serum Institut, Copenhagen, Denmark: Steen Hoffmann, Susan Cowan; Health Board, Tallinn, Estonia: Rita Peetso, Jelena Viktorova; Hospital Saint Louis, Paris, France: Ndeindo Ndeikoundam, Beatrice Bercot; Helsinki University Central Hospital, Helsinki, Finland: Anu Patali Sampo, Vesa Kijaivainen; Vivantes Klinikum Neukolln, Berlin, Germany: Susanne Buder, Klaus Jansen; Hellenic Pasteur Institute, Athens, Greece: Vivi Mliariou, National Centre for Epidemiology, Budapest, Hungary: Eszter Balla, Mária Dudás; Lundspitali University Hospital, Reykjavik, Iceland: Guðrún Sigmundsdottir, Lena Ros Asmundsdottir; St James’s Hospital, Dublin, Ireland: Sinéad Saab, Brendan Crowley; Istituto Superiore di Sanita, Rome, Italy: Anna Caramanente, Paola Stefanelli; Riga East University Hospital, Riga, Latvia; Gaits Pakarna, Violeta Macurtko; Mater Dei Hospital, Msida, Malta: Robert Cassar, Christopher Barbarta, Francesca Vella; The Public Health Service of Amsterdam, Amsterdam, The Netherlands: Alje Van Dam, Ineke Linde; Domain of Infectious Disease Control and Environmental Health, Oslo, Norway: Dominique Amsters.
Caugant, Hilde Kleveland; Medical University of Warsaw, Warsaw, Poland. Beata Mlynarczyk-Bonikowska; Instituto Nacional de Saude Dr Ricardo Jorge, Lisboa, Portugal: Maria-Jose Borrego; Medixir a.s., Bratislava, Slovak Republic. Peter Pavlik, Instituts zur mikrobiologishe im immunologishe, Universa / Ljubljana, Slovenia: Irena Klavš, Tanja Kustec, National Institute of Health Carlos III, Madrid, Spain: Julio Vazquez, Asuncion Diaz, Raquel Abad Torreblanca; Public Health Agency of Sweden, Stockholm, Sweden: Inga Velicko, Magnus Unemo; Royal Infirmary of Edinburgh, Edinburgh, UK: Helen Fifer, Kate Templeton.

Author contributions
MC, MD, GS, BB, SJ, NW, MIVdW, AAG and MU designed, initiated and coordinated the study. SJ, MD, CK, NS and Network members coordinated and performed the laboratory analyses. Patient data was supplied by the Network members. MD, MC, GS, BB, SJ, NW, MIVdW, AAG and MU analysed and interpreted all the data, and wrote a first draft of the paper. MD, MC, CK, NS, GS, BB, SJ, NW, MIVdW, AAG and MU read, commented and approved the final manuscript. All authors read and approved the final manuscript.

Funding
The study was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2017/004). The funding body designed, initiated and coordinated the study as well as assisted in the interpretation of the data, development and final approval of the manuscript.

Availability of data and materials
The data that support the findings of this study are available from the European Centre for Disease Prevention and Control but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the European Centre for Disease Prevention and Control.

Declarations
Ethics approval and consent to participate
All examined gonococcal isolates were cultured and preserved as part of the routine diagnostics (standard care), and isolates or data were submitted to the Euro-GASP surveillance study with no patient identification information. Separate ethical approval was therefore not required.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 UK Health Security Agency, London, UK. 2 WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden. 3 European Centre for Disease Prevention and Control, Stockholm, Sweden. 4 University College London (UCL), London, UK.

Received: 7 March 2022 Accepted: 27 May 2022 Published online: 07 June 2022

References
1. Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance. 2018;23(27).
2. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhoea. N Engl J Med. 2016;374(25):2304–6.
3. Katz AR, Komeya AY, Kirkaldy RD, Whelen AC, Soge OQ, Papp JR, et al. Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis. 2017;65(6):918–23.
4. Montia-Ishihara T, Unemo M, Furubayashi K, Kawahata T, Shimuta K, Nakayama S, et al. Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant-STI407 strain of Neisseria gonorrhoeae. J Antimicrob Chemother. 2014;69(8):2086–90.
5. Poncin T, Fouere S, Braille A, Cameleina F, Aigou M, Bebear C, et al. Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017. Eurosurveillance. 2018;23(21).
6. Yan J, Chen Y, Yang F, Ling X, Jiang S, Zhao F, et al. High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J Antimicrob Chemother. 2021;76(4):936–9.
7. Day MJ, Sptseri G, Jacobsson S, Woodford N, Amato-Gauci AJ, Cole MJ, et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infect Dis. 2018;18(1):609.
8. Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASp): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health. 2019;16(5):412–25.
9. Unemo M, LLM, Escher M, Eremín S, Cole MJ, Galarza P, Ndowa F, Martin I, Dillon JR, Galas M, Ramon-Pardo P, Weinstock H, Wi T. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. The Lancet Microbe. 2021; https://www.thelancet.com/action/showPdf;jsessionid=52666-5247821%2900171-3.
10. Unemo M, Ross J, Serwin AB, Gomberg M, Csini M, Jensen JS. Background review for the 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2012;23(10):108–26.
11. Unemo M, Ross J, Serwin AB, Gomberg M, Csini M, Jensen JS. European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;2020:55664240949126.
12. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85–92.
13. European Centre for Disease Control. Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe—Indicator monitoring 2019. https://www.ecdc.europa.eu/sites/default/files/documents/TRP-20201125-1523.pdf. 2021.
14. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. http://www.eucast.org. 2019.
15. European Centre for Disease Control. Gonococcal antimicrobial susceptibility surveillance in the European Union/European Economic Area Survey of results for 2019. https://www.ecdc.europa.eu/sites/default/files/documents/Gonococcal-antimicrobial-susceptibility-surveillanc-2019. pdf. 2021.
16. Terkelsen D, Tolstrup J, Johnsen CH, Lund O, Larsen HK, Worning P, et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Eurosurveillance. 2017;22(42).
17. Golparian D, Rose L, Lynam A, Mohamed A, Berict B, Ohnishi M, et al. Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Eurosurveillance. 2018;23(47).
18. Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Eurosurveillance. 2019;24(10).
19. Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New Ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel Mosaic penA gene isolated in Japan. Antimicrob Agents Chemother. 2016;60(7):4339–41.
20. Lahra MM, Martin I, Denczuk W, Jennison AV, Lee KI, Nakayama SI, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4):735–40.
21. Lefebvre B, Martin I, Demczuk W, Deshaies L, Michaud S, Labbé AC, et al. Ceftriaxone-resistant *Neisseria gonorrhoeae*, Canada, 2017. Emerg Infect Dis. 2018;24(2):381–3.

22. Chen SC, Han Y, Yuan LF, Zhu XY, Yin YP. Identification of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain FC428, China. Emerg Infect Dis. 2019;25(7):1427–9.

23. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf. 2019.

24. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations Reports. 2015;64(03):1–137.

25. Selb R, Ruder S, Dudareva S, Tamminga T, Bremer V, Banhart S, et al. Markedly decreasing azithromycin susceptibility of *Neisseria gonorrhoeae*, Germany, 2014 to 2021. Eurosurveillance. 2021;26(31).

26. Lahra MM, Shoushtari M, George CRR, Armstrong BH, Hogan TR. Australian gonococcal surveillance programme annual report, 2019. Commun Dis Intell. 2018;2020:44.

27. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI management guidelines for use in primary care. http://www.stiguideines.org.au/sexually-transmissible-infections/gonorrhoea/. 2016.

28. Jacobsson S, Cole MJ, Spiteri G, Day M, Unemo M. Associations between antimicrobial susceptibility/resistance of *Neisseria gonorrhoeae* isolates in European Union/European Economic Area and patients’ gender, sexual orientation and anatomical site of infection, 2009–2016. BMC Infect Dis. 2021;21(1):273.

29. Dong HV, Pham LQ, Nguyen HT, Nguyen MXB, Nguyen TV, May F, et al. Decreased cephalosporin susceptibility of oropharyngeal *Neisseria* species in antibiotic-using men who have sex with men in Hanoi, Vietnam. Clin Infect Dis. 2020;70(6):1169–75.

30. Furuya R, Onoie Y, Karayama A, Saika T, Iyoda T, Tatewaki M, et al. Antimicrobial resistance in clinical isolates of *Neisseria subflava* from the oral cavities of a Japanese population. J Infect Chemother. 2007;13(5):302–4.

31. Laumen JGE, Van Dijck C, Abdellati S, Manoharan-Basil SS, De Baetselier I, Martiny D, et al. Markedly reduced azithromycin and ceftriaxone susceptibility in commensal *Neisseria* species in clinical samples from Belgian men who have sex with men. Clin Infect Dis. 2020;70(6):1169–75.

32. Spratt BG, Bowler LD, Zhang QY, Zhou J, Smith JM. Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal *Neisseria* species. J Mol Evol. 1992;34(2):115–25.

33. Unemo M, Shiander WM. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.

34. Lewis DA. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant *Neisseria gonorrhoeae* strains? Sex Transm Infect. 2015;91(4):234–7.

35. Kong FY, Homer F, Unemo M, Hocking JS. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother. 2019;74(5):1157–66.

36. Cole MJ, Quentin C, Jacobsson S, Day M, Amato-Gauci AJ, Woodford N, et al. The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for *Neisseria gonorrhoeae* in the European Union/European Economic Area. BMC Infect Dis. 2019;19(1):1040.

37. Harris SR, Cole MJ, Spiteri G, Sánchez-Buxó L, Golparian D, Jacobsson S, et al. Public health surveillance of multidrug-resistant clones of *Neisseria gonorrhoeae* in Europe: a genomic survey. Lancet Infect Dis. 2018;18(7):758–68.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.